ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2013
Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation.Leukemia · 2023Trial
- Trial
- Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.Cancer · 2013Trial
- A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data.PharmacoEconomics · 2026Article
- The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma-a single-centre, qualitative service evaluation study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.Advances in therapy · 2024Article
- Article
- Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.JAMA network open · 2023Article
- Patient-reported cognitive function among hematopoietic stem cell transplant and cellular therapy patients: a scoping review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Observational
- Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.Blood advances · 2022Article
- Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program.Annals of hematology · 2021Observational
- Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma.Mediterranean journal of hematology and infectious diseases · 2021Article
- Evolving impact of long-term survival results on metastatic melanoma treatment.Journal for immunotherapy of cancer · 2020Review
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.Journal for immunotherapy of cancer · 2020Article
- Factors influencing supportive care needs of multiple myeloma patients treated with chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.PloS one · 2020Article
- [Patient-reported outcome and its application in hematological neoplasm].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study.BMC cancer · 2019Article
- Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.Journal of managed care & specialty pharmacy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile the impact of various treatments on myeloma patients' health-related quality of life (HRQL) has been reported, the impact of a treatment-free interval (TFI) is currently unclear. The aims of this study were to assess if (1) a TFI is associated with a better HRQL vs. other treatment phases and (2) the length of the TFI influences HRQL.
methodsA cross-sectional postal survey was conducted in the UK. The survey was sent to 605 multiple myeloma patients via the charity Myeloma UK and asked patients to rate their HRQL using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ-MY20 and the EQ-5D. The results were analysed using ordinary least squares regression.
resultsSurveys of 402 (67 %) were returned; 370 (61 %) were considered eligible for analysis. Results demonstrated that being in a first TFI relative to other treatment phases and experiencing a longer TFI were significantly associated with better HRQL as assessed by various domains of the QLQ-C30, MY20 and EQ-5D.
conclusionPatients enjoy better HRQL when in their first TFI, and the length of the TFI also positively impacts on HRQL This information may be important for patients and their physicians making treatment decisions and has implications for treatment protocols incorporating extended therapy.
Indexed as
Identifiers
22886429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.